LeonaBio (LONA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
11 May, 2026Executive summary
The 2026 annual meeting will be held virtually on June 22, 2026, with voting on key proposals including director elections, auditor ratification, executive compensation, and advisory vote frequency.
Stockholders of record as of May 1, 2026, are eligible to vote, with multiple voting methods available including internet, phone, and mail.
Proxy materials and the annual report are accessible online, with a focus on reducing environmental impact and costs.
Voting matters and shareholder proposals
Proposal 1: Election of three Class III directors for three-year terms.
Proposal 2: Ratification of Ernst & Young LLP as independent auditor for fiscal year 2026.
Proposal 3: Advisory approval of named executive officer compensation (Say-on-Pay).
Proposal 4: Advisory vote on frequency of Say-on-Pay (board recommends every three years).
Proposal 5: Other business as may properly come before the meeting.
Board of directors and corporate governance
Board consists of 10 directors, nine of whom are independent; divided into three classes with staggered terms.
Board committees include audit, compensation, nominating and corporate governance, and compliance, each with defined responsibilities.
Board diversity is emphasized, considering experience, gender, race, and ethnicity.
Recent changes include appointments of Peter B. Silverman and Natalie C. Holles as directors, pursuant to investor rights.
Insider trading and code of ethics policies are in place, with robust communication channels for stockholders.
Latest events from LeonaBio
- Virtual annual meeting to vote on directors, auditor, and executive pay, all board-recommended.LONA
Proxy filing11 May 2026 - Q1 2026 net loss rose to $32.9M as R&D spending increased; cash covers 12 months, more funding needed.LONA
Q1 20267 May 2026 - Lasofoxifene plus abemaciclib shows strong promise for ESR1-mutated metastatic breast cancer.LONA
Status update30 Apr 2026 - Registering 5.5M shares for resale; proceeds from warrant exercise support drug pipeline.LONA
Registration filing31 Mar 2026 - 58.5M shares registered for resale; warrant exercises could yield over $146M for clinical programs.LONA
Registration filing31 Mar 2026 - Secured lasofoxifene license, raised $90M, and advanced clinical pipeline amid higher R&D spend.LONA
Q4 202526 Mar 2026 - All proposals, including key share issuances and governance changes, were approved by majority vote.LONA
EGM 202618 Mar 2026 - Proposal 6 is now routine, enabling discretionary broker voting at the March 2026 meeting.LONA
Proxy Filing10 Mar 2026 - Shareholders to vote on major share issuances, new equity plan, and increased authorized stock.LONA
Proxy Filing23 Feb 2026